UK Markets close in 7 hrs 58 mins
  • FTSE 100

    5,866.06
    -18.59 (-0.32%)
     
  • FTSE 250

    17,793.68
    -72.40 (-0.41%)
     
  • AIM

    972.86
    -2.25 (-0.23%)
     
  • GBP/EUR

    1.0982
    -0.0013 (-0.12%)
     
  • GBP/USD

    1.2922
    -0.0019 (-0.1473%)
     
  • BTC-GBP

    9,147.65
    +607.87 (+7.12%)
     
  • CMC Crypto 200

    239.94
    +6.27 (+2.68%)
     
  • S&P 500

    3,426.92
    -56.89 (-1.63%)
     
  • DOW

    28,195.42
    -410.89 (-1.44%)
     
  • CRUDE OIL

    40.76
    -0.07 (-0.17%)
     
  • GOLD FUTURES

    1,903.50
    -8.20 (-0.43%)
     
  • NIKKEI 225

    23,567.04
    -104.09 (-0.44%)
     
  • HANG SENG

    24,529.51
    -12.75 (-0.05%)
     
  • DAX

    12,786.78
    -67.88 (-0.53%)
     
  • CAC 40

    4,919.94
    -22.68 (-0.46%)
     

JHBP (CY) Holdings Limited (6998.HK) Successfully listed on the Main Board of SEHK

·2-min read


EQS-News / 07/10/2020 / 12:29 UTC+8

 

JHBP (CY) Holdings Limited (6998.HK) Successfully

listed on the Main Board of SEHK

 

JHBP (CY) Holdings Limited ("Genor Biopharma" or the "Company"; stock code: 6998.HK), a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs, was successfully listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") at 9:00am today, with a board lot of 500 Shares each.

 

Goldman Sachs (Asia) L.L.C., J.P. Morgan Securities (Far East) Limited and Jefferies Hong Kong Limited are the Joint Sponsors, Goldman Sachs (Asia) L.L.C., J.P. Morgan Securities (Asia Pacific) Limited and Jefferies Hong Kong Limited are the Joint Global Coordinators, Goldman Sachs (Asia) L.L.C., J.P. Morgan Securities (Asia Pacific) Limited (in relation to the Hong Kong Public Offering), J.P. Morgan Securities plc (in relation to the International Offering), Jefferies Hong Kong Limited, CMB International Capital Limited, China Renaissance Securities, Haitong International Securities Company Limited and Macquarie Capital Limited are the Joint Bookrunners and Joint Lead Managers; Futu Securities International (Hong Kong) Limited and US Tiger Securities Inc. are the Joint Lead Managers.

 

Dr. GUO Feng, Executive Director and Chief Executive Officer of JHBP (CY) Holdings Limited, said, "We are very grateful for the support and attention from all the investors. Listing in Hong Kong not only allows Genor Biopharma to enter the international trade market but also provides a solid foundation for the long-term development of Genor Biopharma. Looking forward, our mission is to become a biopharmaceutical engine in discovery, research, development, manufacturing and commercialization of innovative therapeutics initially for patients in China and gradually for patients globally. We will also further strengthen the Company's position in the industry to create the greatest value for the stakeholders."

 

 



File: JHBP (CY) Holdings Limited (6998.HK) Successfully listed on the Main Board of SEHK

07/10/2020 Dissemination of a Marketing Press Release, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com

show this
show this